Evolva Holding SA / Key word(s): Agreement/Development of Sales
12-May-2022 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Reinach, May 12, 2022 – Evolva (SIX:EVE), a pioneer in the field of natural molecules and industrial biotech, today announced the signing of a distribution agreement with Tovani Benzaquen Ingredients (“Tovani”; tovani.com.br) to jointly develop the Brazilian business for Veri-teTM Resveratrol.
The agreement provides Evolva with access to an attractive segment of the Brazilian market for dietary supplements. Revenues are expected to exceed a minimum of CHF 1.5 million over the next 2.5 years from this partnership. Evolva’s Veri-teTM Resveratrol is approved for sale in dietary supplements in Brazil by the Brazilian regulator ANVISA (Agência Nacional de Vigilância Sanitária) and the signing of this distribution agreement with Tovani now allows Evolva to capitalize on the market potential.
Elzo Benzaquen, CEO of Tovani, comments: “As a leading player in this relevant market segment for Veri-teTM Resveratrol in Brazil, Tovani is keen to develop this business together with our partner Evolva. The trend towards healthier and more conscious lifestyles strongly supports functional ingredients based on nature such as Evolva’s Resveratrol. We are excited to offer the differentiating benefits of Veri-teTM Resveratrol, which have been demonstrated in clinical trials such as the reputed RESHAW Study, to our customers.”
Christian Wichert, CEO of Evolva, adds: “The distribution agreement with Tovani marks an important milestone for our company. It opens-up the Brazilian market for our Veri-teTM Resveratrol offering. Veri-teTM Resveratrol is today the main pillar of our Health Ingredients business and a key contributor to our initiatives to significantly boost future growth. Today’s agreement further underlines the positive market momentum for Evolva.”
For Evolva multimedia content, please visit: evolva.com/multimedia-library.
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
End of ad hoc announcement
|Company:||Evolva Holding SA|
|Phone:||+41 61 485 20 00|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1350295|
|End of Announcement||EQS News Service|